Nucelion Therapeutics and VeGen Bio have partnered to advance manufacturing and commercialisation of CAR-T cell therapies in India. (A representative image)

  Nucelion Therapeutics, a specialised cell and gene therapy contract research, development, and manufacturing organisation (CRDMO), and VeGen Bio entered into a partnership to transfer technology, conduct clinical manufacturing, and commercialise innovative cell therapies in India.

Under the agreement, Nucelion, a wholly owned subsidiary of Bharat Biotech, will serve as the technology transfer and clinical- and commercial-stage manufacturing partner for VeGen Bio’s lead candidate, VL-2511, a first-in-class dual BCMA/CD19 autologous CAR-T therapy for multiple myeloma into its single-site GMP manufacturing facility, designed to meet CDSCO, US FDA, and EMA regulatory standards.

The companies will also focus on process optimisation, manufacturing yields, and operational efficiency to improve production economics, aiming to reduce manufacturing costs and improve access to advanced cell therapies in India.

“Our work on VeGen’s dual-target CAR-T program shows that model in action and builds the capacity India needs to bring these therapies to more patients. As our facility is designed to meet US FDA and EMA standards, companies can also commercially launch their products worldwide,’’ Raghu Malapaka, PhD, CBO, Nucelion Therapeutics said in a release on Wednesday.

“This partnership combines complementary strengths, providing VeGen Bio with a pathway to technology transfer, manufacturing, and pipeline expansion, while enabling our CDMO partner to establish and grow its cell therapy manufacturing capabilities,’’ Prashant Bhavar, Director, VeGen Bio, said.

Published on October 21, 2026